AMGEN Inc

NASDAQ: AMGN
$321.60
-$0.19 (-0.1%)
Real Time Data Delayed 15 Min.

AMGN Articles

The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline potential at current levels.
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if...
The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After all, a cure or...
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.